Quest Diagnostics (DGX) Cash from Financing Activities (2009 - 2026)

Quest Diagnostics has reported Cash from Financing Activities for 18 years, with the latest figure at -$229.0 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 21.84% year-over-year to -$229.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$915.0 million (down 222.65% YoY) and the FY2025 annual result came in at -$1.4 billion, down 228.04% from the prior year.
• Cash from Financing Activities slipped to -$229.0 million in Q2 2026 per DGX's latest filing, from -$152.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.8 billion in Q3 2024 and troughed at -$561.0 million in Q1 2025.
• A 5-year average of -$125.4 million and a median of -$235.5 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 1147.37% in 2022, then jumped 2232.53% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$545.0 million in 2022, then soared by 123.85% to $130.0 million in 2023, then tumbled by 230.77% to -$170.0 million in 2024, then slumped by 68.82% to -$287.0 million in 2025, then increased by 20.21% to -$229.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$229.0 million, -$152.0 million, and -$287.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.